AbbVie’s Parkinson’s Drug, Kaken’s Eschar Remover Skip March Listing

AbbVie’s Parkinson’s drug Vyalev (foslevodopa + foscarbidopa) and Kaken Pharmaceutical’s burn eschar remover NexoBrid took a pass on their reimbursement listing for March. Both drugs had been granted Japanese approval in December. The two products were not on the roster...read more